Hair loss affects an estimated 50 million men and 30 million women in the United States. While FDA-approved options like minoxidil and finasteride remain first-line, a growing body of research has examined whether certain peptides could play a supportive role in follicle biology. This review covers five peptides that appear in the published literature — what mechanism researchers have proposed, what evidence exists, and what is still unknown.
Important: No peptide discussed here is FDA-approved as a hair loss treatment. Compounded peptide protocols are available subject to evaluation by a licensed provider; approval is not guaranteed.
1. GHK-Cu (Copper Tripeptide-1): The Most-Studied Option
GHK-Cu is a naturally occurring tripeptide — glycine, histidine, lysine — that binds copper and is found in human plasma, saliva, and urine. Its concentration declines with age, which has prompted research into topical supplementation.
Proposed mechanism: GHK-Cu appears to stimulate hair follicle enlargement, extend the anagen (active growth) phase, and promote follicular keratinocyte proliferation. Copper plays a known role in melanin synthesis and connective tissue remodeling, both relevant to follicle structure.
What the research shows: A 2022 review published in Cosmetics (PMID 27489425) identified GHK-Cu as one of the more extensively studied copper complexes in dermatological applications, noting activity in scalp-focused studies. Topical formulations have been used in cosmetic products for decades. Small-scale comparative studies have shown increases in hair density with topical GHK-Cu versus control, though large-scale randomized controlled trials remain limited.
Route in research: Topical (serum, lotion). Typically applied directly to the scalp.
2. AHK-Cu (Alanine-Histidine-Lysine Copper): The Newer Analog
AHK-Cu is a synthetic analog of GHK-Cu, designed with modifications intended to improve follicular penetration and binding stability.
Proposed mechanism: Similar to GHK-Cu — copper chelation supporting follicle signaling pathways — but with a structural variation (alanine substituted for the terminal glycine) that researchers have proposed may enhance dermal penetration.
What the research shows: A study published in Archives of Dermatological Research (PMID 17703734) examined AHK-Cu in the context of follicular activity and found results suggesting comparable or enhanced activity relative to GHK-Cu in that model. The dataset is substantially smaller than GHK-Cu's, and head-to-head human trials are not yet published.
Route in research: Topical. Often studied in comparison to GHK-Cu formulations.
3. BPC-157 (Body Protective Compound): Tissue Repair Effects
BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found in gastric juice. It has been studied primarily in the context of tissue healing, tendon repair, and angiogenesis — the formation of new blood vessels.
Proposed mechanism for hair: Researchers have proposed that BPC-157's angiogenic effects could theoretically support dermal papilla vascularization, which is necessary for follicle nutrient delivery. Follicles in the anagen phase have high metabolic demand and rely on a rich capillary network.
What the research shows: Available evidence for BPC-157 and hair is indirect. Studies demonstrating its angiogenic and tissue-repair properties in animal models are published (PMC10840484), but direct studies in alopecia models or human participants have not been published as of this writing. See also our full BPC-157 patient guide for more on its broader research profile.
Route in research: Subcutaneous injection (systemic). Not studied topically for hair.
4. TB-500 (Thymosin Beta-4 Analog): Wound Healing and Actin Regulation
TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring peptide involved in actin polymerization, cell migration, and wound healing. It is studied primarily for recovery and tissue repair applications.
Proposed mechanism for hair: Thymosin Beta-4 is expressed in the hair follicle. Research has proposed that it plays a role in activating follicle stem cells, particularly in the wound-healing response. A 2010 paper in the Journal of Investigative Dermatology found that Thymosin Beta-4 promoted hair follicle stem cell activation in a murine wound model.
What the research shows: Evidence is mostly in animal wound models. The connection to non-wound-related hair loss (such as androgenetic alopecia) is speculative. Human data is not available. TB-500's broader tissue-repair evidence base is covered in our TB-500 tissue repair overview.
Route in research: Subcutaneous injection (systemic).
5. LMWCP (Low Molecular Weight Collagen Peptides): Scalp Extracellular Matrix
Low molecular weight collagen peptides are hydrolyzed collagen fragments that have been studied for skin, nail, and hair structural support. Unlike the signaling peptides above, their proposed mechanism is primarily nutritional and structural rather than hormonal or angiogenic.
Proposed mechanism: Collagen provides the scaffolding for the dermal papilla and the extracellular matrix surrounding the follicle. Oral LMWCP supplementation has been proposed to increase the availability of proline, hydroxyproline, and glycine — amino acids involved in follicle structural proteins.
What the research shows: A randomized, double-blind, placebo-controlled trial published in Journal of Cosmetic Dermatology (PMID 42072405) examined oral LMWCP supplementation and reported improvements in hair thickness and scalp coverage metrics compared to placebo over 6 months. This represents some of the more rigorous recent data in the peptide-hair space, though the mechanism remains structural rather than pharmaceutical.
Route in research: Oral supplementation.
Evidence Comparison at a Glance
| Peptide | Proposed Mechanism | Strongest Evidence | Route |
|---|---|---|---|
| GHK-Cu | Follicle enlargement, anagen extension | Small human topical studies; cosmetics literature | Topical |
| AHK-Cu | Copper chelation, enhanced penetration | In-vitro & small comparative studies | Topical |
| BPC-157 | Angiogenesis, vascular support | Animal tissue repair models (indirect) | Injection |
| TB-500 | Stem cell activation, wound response | Murine wound model (indirect) | Injection |
| LMWCP | Structural amino acid supply | Randomized controlled trial (oral, 6-month) | Oral |
What This Means Clinically
The evidence base for peptides and hair growth is uneven. GHK-Cu has the longest track record in applied cosmetic research. LMWCP has arguably the most rigorous recent trial design. BPC-157 and TB-500 have robust evidence for tissue repair and vascular effects, but their application to hair loss is indirect and largely theoretical at this time.
No peptide discussed here is a substitute for FDA-approved hair loss treatments, and none is approved by the FDA specifically for alopecia. Individuals exploring peptide protocols should do so with a licensed provider who can evaluate their full health picture.
At TelosRX, our asynchronous telehealth model allows you to submit your health history and have a licensed provider review your profile without scheduling a real-time appointment. Compounded peptide protocols are available subject to provider approval — approval is not guaranteed.
Frequently Asked Questions
Do peptides actually help with hair growth?
Some peptides have shown activity in preclinical and early clinical studies relevant to hair follicle biology. GHK-Cu has the most human study data for topical use; others like BPC-157 and TB-500 have primarily animal or in-vitro evidence. No peptide is FDA-approved as a hair loss treatment.
What is GHK-Cu and how does it relate to hair?
GHK-Cu (copper tripeptide-1) is a naturally occurring copper-binding peptide. Research has explored its role in promoting hair follicle enlargement and extending the anagen (growth) phase. Its concentration in the body declines with age, prompting interest in topical supplementation.
Is BPC-157 studied for hair loss?
BPC-157 has been studied primarily for tissue repair and angiogenesis in animal models. Some researchers have proposed that its vascular effects could theoretically support follicle health, but direct human studies on hair loss are lacking.
Can I get peptides for hair growth at TelosRX?
TelosRX offers asynchronous evaluations for compounded peptide protocols, subject to approval by a licensed provider. Compounded peptides are not FDA-approved. Approval is not guaranteed and depends on your individual health profile.
What is the difference between topical and systemic peptides for hair?
Topical peptides like GHK-Cu are applied directly to the scalp and act locally. Systemic peptides like BPC-157 and TB-500 are administered via injection and act body-wide. The route of administration affects the mechanism, evidence base, and clinical considerations.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.